Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Ex vivo systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Here, we demonstrate the ability to interrogate ex vivo response to ICB using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and myeloid cell populations and respond to ICB in short-term three-dimensional microfluidic culture. Response and resistance to ICB was recapitulated using MDOTS derived from established immunocompetent mouse tumor models. MDOTS profiling demonstrated that TBK1/IKKϵ inhibition enhanced response to PD-1 blockade, which effectively predicted tumor response in vivo. Systematic profiling of secreted cytokines in PDOTS captured key features associated with response and resistance to PD-1 blockade. Thus, MDOTS/PDOTS profiling represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens. Significance: Resistance to PD-1 blockade remains a challenge for many patients, and biomarkers to guide treatment are lacking. Here, we demonstrate feasibility of ex vivo profiling of PD-1 blockade to interrogate the tumor immune microenvironment, develop therapeutic combinations, and facilitate precision immuno-oncology efforts. Cancer Discov; 8(2); 196–215. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Deng et al., p. 216. This article is highlighted in the In This Issue feature, p. 127
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We did not observe an effect of IgG4 antibody control (Extended Data Fig. 2b), consistent with previous reports 14,19 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ex vivo profiling using murine-derived organotypic tumour spheroids (MDOTS) 14 derived from untreated mice bearing B16-ova tumours confirmed enhanced response to anti-PD-1 plus TBK1i (Fig. 1e).”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“and that disrupting TBK1 signaling has shown early promise enhancing response to ICB in murine tumour models 14,15 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“Although reported sources of CCL19 and CXCL13 include stromal, immune, and tumor cells, a recent high-resolution study using single-cell RNA sequencing (RNA-seq) of melanoma specimens demonstrated CCL19 expression in cancer-associated fibroblasts (CAF) and CXCL13 with CD8+ exhausted T cells (46).”
BackgroundSelf-citationSpatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422 · cited 2×
“As PD-1 blockade promotes immune cell infiltration in vivo (13), we also performed singlesample gene set enrichment analysis (ssGSEA) using published immune signatures (37), which revealed enrichment of diverse immune cell populations in a subset of patients (group A) treated with ICB (Fig.”
Method
Research works printed but not linked: 1
- Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–11. doi: 10.1126/science.aad0095. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
Cited by
Items 501–589 of 589
Decoding drug resistance and apoptosis in biliary tract cancers using 3D tumor models
Gill, G. S., Sahoo, O. S., Nayek, A., Sarkar, S. K., Kurdia, K. C., Bhardwaj, N., Das, C. J., Galodha, S., Goyal, G., Karmakar, S., et al. (2026) · Frontiers in Cell Death · doi:10.3389/fceld.2026.1819303 · Cited by 1
Silva, P. D., Wekking, D., Choe, J. J., Kidd, M. D., Pearce, J. L., Castellanos, D. M. R., Zelga, P. J., Jenkins, R. W., Wang, K. K., Chandrasekhara, V., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805948 · Cited by 2
Self-citationPatient-derived models of prostate cancer: Capturing tumour complexity from initiation to metastasis
Magnen, C. L., Brennen, W. N., Aytés, À., Bock, N., Bristow, R. G., Choo, N., Chua, C. W., Clark, A. K., Clements, J. A., Coleman, I. M., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218791 · Cited by 1
Clegg, J., Davern, J. W., Holloway, P. L., McFetridge, M. L., Ravichandran, A., Jeffery, P. L., Hilmi, F. S., Murekatete, B., Dargaville, T. R., Werner, C., et al. (2026) · Materials Today Advances · doi:10.1016/j.mtadv.2026.100986 · Cited by 1
Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection
Ezeonwumelu, I. J., García-Vidal, E., Riveira‐Muñoz, E., Felip, E., Gutiérrez-Chamorro, L., Calba, I., Massanella, M., Sirera, G., Clotet, B., Ballana, E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315000 · Cited by 1
Evaluation of Multispecific Drugs Based on Patient‐Derived Immunocompetent Tumor Organoids
Zhao, Z., Wu, X., Zhang, T., Zhou, M. R., Liu, S., Yang, R. L., & Li, J. (2025) · ChemBioChem · doi:10.1002/cbic.202400731 · Cited by 1
Durymanov, M. O. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297924604234 · Cited by 1
“…and colleagues developed the patient-derived organotypic tumor spheroids (PDOTS) of six different cancer types BIOCHEMISTRY (Moscow) Vol. 90 No. 2 2025 using the scaffold-free method, which was followed by embedding them into the ECM-mimicking scaffold and culturing in a microfluidic system [29].”
Alsubaiti, A., Alamir, H., Huynh, L., Grant, T., Aljohani, A., Chou, P. H., Shi, Y., Alismail, M., Mason, L. R., Herman, A., et al. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf023 · Cited by 1
Innate αβ T-Cells Mediate Anti-Tumor Immunity by Orchestrating Immunogenic Macrophage Programming
Mishra, A., Barry-Hundeyin, M., Kurz, E., & Miller, G. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2019.08.586 · Cited by 1
[Application of Organoids in Lung Cancer Precision Medicine].
Jia, Z., Liang, N., & Li, S. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.101.20 · Cited by 2
Self-citationExpanding the precision oncology toolkit with micro-organospheres for early cancer diagnosis
Vandana, J. J., Lacko, L. A., & Chen, S. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.05.002 · Cited by 1
3D models for melanoma γδ T cell‐based immunotherapy
Huber, V., Vallacchi, V., Daveri, E., & Vergani, E. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.926 · Cited by 1
The Intersection of Biomaterials, Tissue Engineering, and Immuno-oncology
Clevenger, A. J., VandenHeuvel, S. N., & Raghavan, S. A. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166013-00342 · Cited by 1
Towards a scaled-up T cell-mediated cytotoxicity assay in 3D cell culture using microscopyPreprint
Gottschalk, E. Y., Czech, E., Aksoy, B. A., Aksoy, P., & Hammerbacher, J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/842039 · Cited by 1
“Recently, 3D cell culture systems have been explored in immunotherapy research, with studies using material from patient or mouse tumors to generate spheroids that retain tumor architecture (Jenkins et al. 2018; Deng et al. 2018; Pavesi et al. 2017; Courau et al. 2019).”
BackgroundMethodInfluentialA 96-WELL VALVED MICROFLUIDIC DEVICE FOR TESTING OF LIVE INTACT TUMOR CUBOIDSPreprint
Lockhart, E. J., Horowitz, L. F., Lim, C., Nguyen, T., Mehrabi, M., Gujral, T. S., & Folch, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.07.499178 · Cited by 1
“The μDTs were minced manually with a scalpel and grown in collagen gel either on Transwells 29 or in microchannels.(25,26) Astolfi et al.”
MethodGFPT2 controls immune evasion in EGFR-mutated non-small cell lung cancerPreprint
Liu, J., Ao, L., Jia, W., Gong, Q., Cui, J., Wang, J., Yu, Y., Fu, C., Li, H., Jia, W. P., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4203208/v1 · Cited by 2
CREB5 promotes immunotherapy resistance via tumor-intrinsic collagen matrix depositionPreprint
Tiwari, P., Colvin, K. J., Kim, S. Y., Kammula, A. V., Chinai, J. M., Alfaiate, N., Revach, O., Kistler, E. N., Heo, S., Anderson, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.22.649109 · Cited by 1
Self-citationMolecular basis for targeting TBK1 in CAR-T cell therapies for cancer
Cattaneo, G., Ventin, M., Maggs, L., Sun, Y., Ferrone, C. R., & Jenkins, R. W. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2545845 · Cited by 1
“Pharmacologic inhibition of TBK1 was shown to enhance T cell effector function through multiple mechanisms, including increased secretion of effector cytokines, prevention of T cell exhaustion, and promotion of de-differentiated effector T cell states [8,10].”
Self-citationPan, Y., Qiu, Y. L., Jiang, D., Liu, X., Gu, C., Wan, H., & Wang, P. (2019) · IEEE International Conference on Nano/Molecular Medicine and Engineering (NANOMED) · doi:10.1109/nanomed49242.2019.9130615
“When cells are suspended in hydrogels, they receive uneven chemical concentrations from the surrounding environment[4].”
BackgroundOvarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids
Volpari, T., Hebner, J., Aiyar, R. S., & Martin, L. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00080-3
Technical advances in pluripotent stem cell-derived and tumorigenic organoids
Kang, S., Bong, E. K., Kim, H., & Roh, T. (2022) · Organoid · doi:10.51335/organoid.2022.2.e18
Introduction on Personalized Immune-Oncology
Abadi, B., & Rezaei, N. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_286-1
Preclinical Cancer Models for the Evaluation of Immunotherapies: From Cell Lines to Animal Models
Pezeshki, P. S., & Rezaei, N. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_206-1 · Cited by 1
Modeling of the Tumor Microenvironment in Tumor Organoids
Shelkey, E., Dominijanni, A. J., Forsythe, S. D., Oommen, D., & Söker, S. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166013-00279 · Cited by 1
Ramsay, R. G., Whitehall, V., & Flood, M. P. (2023) · Growth Factors · doi:10.1080/08977194.2023.2227274
“This information is beginning to guide genuine patient (tumor)-specific treatments (Flood et al. 2022; Ganesh et al. 2019; Jenkins et al. 2018; Narasimhan et al. 2020; Ooft et al. 2019).”
BackgroundInfluentialSingh, S. K., Ahuja, A., Ramankutty, R., & Ramaswamy, S. (2023) · Current Drug Therapy · doi:10.2174/0115748855266739230919110125
Use of Organoids in Cancer: A New Therapeutic and Research Approach
Tonon, S., Martinis, E., Secco, C. D., Tosoni, L., Tomadini, G., Vitale, G., Pucillo, C. E. M., & Frossi, B. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_285-1
Suvilesh, K. N., Manjunath, Y., Nussbaum, Y. I., Gadelkarim, M., Srivastava, A., Li, G., Warren, W. C., Shyu, C., Gao, F., Ciorba, M. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.18.562944
Song, F., & Chen, Z. (2023) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v31.i24.989
Acosta-Plasencia, M., Menauer, P., Marrades, R. M., & Navarro, A. (2024) · Springer eBooks · doi:10.1007/978-3-030-80962-1_387-1
Human organs-on-a-chip for cancer modeling
Hegde, M., Girisa, S., & Harsha, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13782-2.00005-x
An Overview of the Bench to Bedside Models of Breast Cancer in the Era of Cancer Immunotherapy
Kwan, A., Stark, K., Allen, R. J., Ottewell, P. D., & Muthana, M. (2024) · Medical Research Archives · doi:10.18103/mra.v12i6.5514
Nguyen, H. T., Pietraszek, N., Shelton, S. E., Arthur, K., & Kamm, R. D. (2024) · Journal of Biomedical Optics · doi:10.1117/1.jbo.29.s2.s22710 · Cited by 1
Self-citationFeng, F., He, T., Lin, P., Hu, J., Shen, B., Tang, Z., Zhou, J., Jia, F., Hu, B., & Li, H. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102276 · Cited by 3
Introduction to modern technological advancement for supervising human health
Lahiri, D., Mazumder, S., Bhattacharya, D., & Nag, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33351-4.00007-6
BIOPRINTING OF MICRODISSECTED TUMOR “CUBOIDS” IN HYDROGELSPreprint
Bansal, A. M., Horowitz, L. F., Yeung, M., Gujral, T. S., & Folch, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.05.671932
Introduction on Personalized Immune-Oncology
Abadi, B., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_286
Use of Organoids in Cancer: A New Therapeutic and Research Approach
Tonon, S., Martinis, E., Secco, C. D., Tosoni, L., Tomadini, G., Vitale, G., Pucillo, C. E. M., & Frossi, B. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_285
Preclinical Cancer Models for the Evaluation of Immunotherapies: From Cell Lines to Animal Models
Pezeshki, P. S., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_206
Acosta-Plasencia, M., Menauer, P., Marrades, R. M., & Navarro, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00763-6_387 · Cited by 1
Tümör-Bağışıklık Hücre Etkileşimlerini Araştırmak İçin Biyomühendisliksel Yöntemler
Topal, T., & Uzun, Z. E. (2025) · Gazi Üniversitesi Fen Fakültesi Dergisi · doi:10.63716/guffd.1768168
Wu, Z., Ao, Z., Cai, H., Li, X., Chen, B., Tu, H., Wang, Y., Lu, R. O., Gu, M., Cheng, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26566340
Deng, Y., Jin, H., Ning, J., Cui, D., Zhang, M., & Yang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26612891
Deng, Y., Jin, H., Ning, J., Cui, D., Zhang, M., & Yang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26612900
Deng, Y., Jin, H., Ning, J., Cui, D., Zhang, M., & Yang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26612897
Deng, Y., Jin, H., Ning, J., Cui, D., Zhang, M., & Yang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26612894
Perry, C., Frey, A., Fei, Y., Wang, J., Costa, P., Amin, H. N., Ghadermarzi, S., Levine, D., Tong, W., Koda, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.09.693245
Self-citationBridging cancer cell-intrinsic driver genes and -extrinsic cell-cell communication with Driver2Comm
Xie, R., Li, J., Hu, Y., & Gao, L. (2026) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013973
Xiong, X., Wang, H., Shu, L., Wen, S., Deng, J., Xia, Y., Yan, X., Fang, Z., Zhang, F., Li, Q., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102091
Self-citationBladder cancer organoids: bridging pathological features and drug response for precision oncology
Zheng, Q., Liao, E., Chen, D., & Shan, G. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05081-9 · Cited by 2
Zhang, G., Yang, H. J., Fu, M., Qin, Y., Cai, W., Hu, Y., Zhang, Y., Zhao, Y., Chen, H., Ding, L., et al. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000005145
“Notably, the inhibition of TBK1 effectively prevents the release of immunosuppressive cytokines and enhances the therapeutic efficacy of anti-programmed death-ligand (PD-L1) therapy [ 34 ] .”
Self-citationZhou, J., Zeng, T., Ye, M., Li, M., Wen, L., Liu, X., Zhang, Z., & Meng, Y. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102748
Organoids as Next-Generation Models of Tumor Drug Resistance
Wang, L., Tang, Q., Zhong, L., He, M., Zhu, X., Zheng, Q., Long, L., Wang, Y., Jiang, Q., Wang, H., et al. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i1.9
Self-citationHypoxia-on-chip : from technological developments to biological applications
Bouquerel, C. (2023) · theses.fr (ABES) · doi:10.70675/d7d58b5dzd927z4235z8c54z8dbb6fd4757e · Cited by 1
Gaps and paths forward in cancer pharmacology and translational research
Hughes, E., Davenport, L. L., Zdyrski, C., Pawlak, A., Mochel, J. P., & Douglass, E. F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1779049
“…chimeras), do not follow the traditional PD-Hill paradigm as efficacy is dependent on multiple targets and/or multiple cell types, requiring new in vitro methods such as co-culture, to evaluate drug efficacy (Shu et al., 2025; Spiridon et al., 2002; Douglass and Miller, 2025; Jenkins et al., 2018).”
Wang, Z., Zhou, L., & Ming, L. (2026) · Gene · doi:10.1016/j.gene.2026.150161
T cells restrain inflammation driven by TNF-induced cell deathPreprint
Přibíková, M., Paprčková, D., Knizkova, D., Synackova, A., Šemberová, T., Drobek, A., Niederlová, V., Michalik, J., Kratochvilova, A., Štěpánek, O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.21.719867
PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer
Li, Z., Fu, C., Sehgal, K., Egloff, A. M., Thai, T. C., Monge, O. A., Chuong, C. L., Senent, Y., Lineberry, M. S., Eschle, B. K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72372-1 · Cited by 2
Self-citationde Man, S. M. A., Aksoy, E. K., Veenendaal, T., Meesters, N., Chavez-Abiega, S., Yan, X., Kop, M., Gandini, L., Flach, J., Meng, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1721016
“Comparable clinical correlations have been reported in high-grade serous ovarian cancer (30), and MoA discovery for PD-1/PD-L1 sensitivity has been demonstrated in alternative ex vivo assays (51) in similar contexts (28, 29).”
Nakano, M., Heo, L., Yang, Y.-P., Munoz, L. P., Liu, Y., Zhao, L., Park, J., Tsekitsidou, E., Francois, A., Liu, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.06.722767
Patient-derived tumor organoid models for functional precision oncology in hepatocellular carcinoma
Han, L., & Song, F. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2025.118
Qin, X., Zhao, Y., Wu, Y., Efelis, A., Paul, R., Islam, K., Marquez, C. S., Liu, Y., & Liu, Y. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01908
Childress, A. R., Esoe, D.-P. I., Song, X., Gosser, C. M., Lin, Y., Plaugher, D. R., DuCote, T. J., Naughton, K. J., Skaggs, E. M., Yang, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.01.725956
“These cultures can be further augmented by varying immune cell ratios, incorporating immune cells from distinct backgrounds (tumor-bearing versus non-tumor-bearing), and blocking specific signaling pathways to assess how these factors influence therapeutic response.”
Wang, H., Liu, L., & Chen, W. (2026) · Nature Protocols · doi:10.1038/s41596-026-01387-1
Patient-derived organoid in vitro models for antibody-based immunotherapy in pediatric solid tumors
Koelewijn, J., Janda, C. Y., & van Noesel, M. M. (2026) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2026.100533
Li, J., Li, J., Zhao, Y., Yu, Y., & Cui, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1853196
“4D spatiotemporal tracking, lineage tracing, in vivo imaging, patient-derived organoids, organotypic tumor spheroids, and autologous TAM co-culture systems can help determine whether TAM states precede, follow, or reinforce tumor-cell lineage transitions (139, 140).”
Tian, Z., He, L., & Zhang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1870393
“Their main drawback is practical: the viable experimental window is short, and controlled perturbation is often more dif fi cult than in reductionist culture systems (12, 39).”
Lupo, B., Catalano, I., & Trusolino, L. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02747-x
Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance
Cordes, N. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03803-6
“Functional 3D models, particularly PDO co-cultures with autologous immune cells [79, 80, 333], are well suited to dissect these dynamics, including adhe-sion-mediated immune exclusion in which a dense, stiff ECM and integrin-dependent signaling act as barriers to T-cell infiltration after…”
Douglas, Y. K., & Adham, S. A. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08763-1
“…patient-matched macrophage polarization states, and regulatory T cell populations would enable meaningful evaluation of immune checkpoint inhibitors and other immunotherapeutic strategies within a 3D context, an application for which current spheroid systems are largely unsuited [316, 317].”
Almeida-Nunes, D. L., Mendes‐Frias, A., Nunes, M., Ferreira, V., Lobo, C., Monteiro, P., Abreu, M. H., Bartosch, C., Nóbrega, C., Dinis‐Oliveira, R. J., et al. (2026) · Cancers · doi:10.3390/cancers18162612
Tumormikroumgebung und Organoidmodelle
Dobrowolski, E.-R., & Jäger, D. (2026) · Forum · doi:10.1007/s12312-026-01611-9
“Dabei stehen neben der biologischen Aussagekraft auch praktische Aspekte wie Etablierungsraten, Durchlaufzeiten und dieIntegrationinklinischeEntscheidungs-strukturen im Fokus [3, 12].”
Zhang, Q., Zeng, H., Wan, X., & Lang, L. (2026) · Cancers · doi:10.3390/cancers18162639
“Sustaining immune function under continuous flow is the other target, and the microfluidic formats developed for it [52–54] are taken up in the following subsection on microfluidic and organ-on-chip refinement.”
Construction and application of mammary and breast cancer organoids
Meng, Y., Bai, P., Zhang, L., Zhang, M., & Cai, C. (2026) · Cell Insight · doi:10.1016/j.cellin.2026.100354
“…murine-derived organotypic tumor spheroids (PDOTS/MDOTS), demonstrating that TBK1/IKK ε inhibitors combined with PD-1 blockade significantly enhanced IFN-γ + CD8 + T cell infiltration and prolonged mouse survival, enabling assessment of monotherapy and combination strategies (Jenkins et al., 2018).”
Tan, C., Wang, B., He, S., Gong, Y., Zhang, L., Wang, H., Tang, Q., Li, X., Xiong, G., Zhou, L., et al. (2026) · medRxiv · doi:10.64898/2026.08.17.26360042
Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development
Gowans, C., Khedr, A., Georgiou, P. G., Arik, N., Sen, O., Rannard, S. P., McDonald, T. O., & Tapeinos, C. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71625
Николаевич, К. А., Krasnoselskaya, E. N., Khanova, A. R., & Николаевич, Ф. С. (2026) · Biomaterials Advances · doi:10.1016/j.bioadv.2026.215141
Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer
Bautista, J., Delgado, M. D. C., Viteri-Recalde, J., Benítez-Núñez, M., Ramírez-Sánchez, D., & López-Cortés, A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1921036
“Organotypic tumour spheroid platforms have already shown that ex vivo systems can profile response to PD-1 blockade while preserving elements of the tumour microenvironment, supporting their use as translational tools for immunotherapy development (Jenkins et al., 2018).”
Liu, Y., Wang, Y., Huang, X., Li, Y., zhu, A., Wang, M., Yao, H., & Liang, L. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108438
Wang, X., Wang, Q., Wang, J., Ding, G., Huang, Y., Feng, Y., & Zou, B. (2026) · Materials Today Advances · doi:10.1016/j.mtadv.2026.100976
Fomina, A., Tam, A., Lam, J., Wu, N. C., Li, N. T., & McGuigan, A. P. (2026) · Advanced Materials Technologies · doi:10.1002/admt.71311
Mechanoresponsive reprogramming of tumor-associated macrophages during cancer progression
Kim, D., Kim, Y., Lee, J., Bajpai, S. K., & Kim, D. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1915582
“In contrast, TAM reprogramming aims to convert M2-like TAMs into M1-like TAMs, thereby transforming the immunosuppressive tumor microenvironment into a more pro-inflammatory state (Jenkins et al., 2018).”
Bılır, A., Yıldırım, B., & Karalök, M. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198775
Advancing functional treatment prediction for precision oncology
Smit, E. C., Komar, Z. M., Blommestein, H. M., Verheul, H. M. W., Jager, A., Tauriello, D. V. F., & van Gent, D. C. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.09.008
Microfabrication techniques for making organ-on-a-chip and body-on-a-chip devices
Azizgolshani, H., & Borenstein, J. T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-16110-0.00021-2
Zhang, Y., Wang, Z., Xiu, Y., Wang, H., Zhao, K., & Chen, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1988538
Metadata
- Authors
- Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., He, M. X., Walker, W., Zhang, G., Tian, T., Cheng, C., Wei, Z., Palakurthi, S., Bittinger, M., Vitzthum, H., Kim, J. W., Merlino, A., Quinn, M., Venkataramani, C., Kaplan, J. A., Portell, A., Gokhale, P. C., Phillips, B., Smart, A., Rotem, A., Jones, R. E., Keogh, L., Anguiano, M., Stapleton, L., Jia, Z., Barzily-Rokni, M., Cañadas, I., Thai, T. C., Hammond, M. R., Vlahos, R., Wang, E. S., Zhang, H., Li, S., Hanna, G. J., Huang, W., Hoang, M. P., Piris, A., Eliane, J.-P., Stemmer-Rachamimov, A. O., Cameron, L., Su, M.-J., Shah, P., Izar, B., Thakuria, M., LeBoeuf, N. R., Rabinowits, G., Gunda, V., Parangi, S., Cleary, J. M., Miller, B. C., Kitajima, S., Thummalapalli, R., Miao, B., Barbie, T. U., Sivathanu, V., Wong, J., Richards, W. G., Bueno, R., Yoon, C. H., Miret, J., Herlyn, M., Garraway, L. A., Van Allen, E. M., Freeman, G. J., Kirschmeier, P. T., Lorch, J. H., Ott, P. A., Hodi, F. S., Flaherty, K. T., Kamm, R. D., Boland, G. M., Wong, K.-K., Dornan, D., Paweletz, C. P., & Barbie, D. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Gilead Sciences (United States) (US)
- Broad Institute (US)
- The Wistar Institute (US)
- New Jersey Institute of Technology (US)
- 11Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
- Brigham and Women's Hospital (US)
- Massachusetts Institute of Technology (US)
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Corresponding author
- Dornan, David
- Barbie, David A.
- ORCID
- Jenkins, Russell W.
- Aref, Amir R.
- Lizotte, Patrick H.
- Ivanova, Elena
- Zhou, Chensheng W.
- Bowden, Michaela
- Deng, Jiehui
- Liu, Hongye
- Miao, Diana
- He, Meng Xiao
- Zhang, Gao
- Tian, Tian
- Cheng, Chaoran
- Wei, Zhi
- Palakurthi, Sangeetha
- Portell, Andrew
- Gokhale, Prafulla C.
- Smart, Alicia
- Rotem, Asaf
- Jones, Robert E.
- Keogh, Lauren
- Jia, Zhiheng
- Barzily-Rokni, Michal
- Cañadas, Israel
- Thai, Tran C.
- Wang, Eric S.
- Zhang, Hua
- Li, Shuai
- Hanna, Glenn J.
- Huang, Wei
- Hoang, Mai P.
- Piris, Adriano
- Stemmer-Rachamimov, Anat O.
- Cameron, Lisa
- Shah, Parin
- Izar, Benjamin
- Thakuria, Manisha
- LeBoeuf, Nicole R.
- Rabinowits, Guilherme
- Parangi, Sareh
- Cleary, James M.
- Miller, Brian C.
- Kitajima, Shunsuke
- Thummalapalli, Rohit
- Barbie, Thanh U.
- Wong, Joshua
- Richards, William G.
- Bueno, Raphael
- Yoon, Charles H.
- Miret, Juan
- Herlyn, Meenhard
- Garraway, Levi A.
- Freeman, Gordon J.
- Lorch, Jochen H.
- Ott, Patrick A.
- Hodi, F. Stephen
- Flaherty, Keith T.
- Kamm, Roger D.
- Boland, Genevieve M.
- Wong, Kwok-Kin
- Paweletz, Cloud Peter
- Barbie, David A.
- Venue
- Cancer Discovery
- Published
- 2018-02-01
- Volume
- 8
- Issue
- 2
- Pages
- 196-215
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5809290
- OpenAlex
- W2766123339
- Cited by
- 594
- References
- 62
- Citations by year
- 2026: 67 · 2025: 76 · 2024: 91 · 2023: 73 · 2022: 76 · 2021: 73 · 2020: 72 · 2019: 37 · 2018: 28
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (NCI) (NCI T32 CA009172-41, 1R01CA149738-01, NCI-R01 CA190394-01, P01CA120964, 5R01CA163896-04, 5R01CA140594-07, 5R01CA122794-10, 5R01CA166480-04)
- SU2C (SU2C-AACR-DT17-15)
- HHS | NIH | National Institute of General Medical Sciences (NIGMS) (NIGMS T32 GM008313)
- National Science Foundation (NSF) (NSF GRFP DGE1144152)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- anti-PD-1 therapy, immune checkpoint blockade, tumor microenvironment, immunotherapy resistance, cytokine production, precision immuno-oncology, combination therapy, microfluidic culture, patient-derived tumor models
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Flow Cytometry, Humans, Immunohistochemistry, Tumor Cells, Cultured, Immunophenotyping, Cytokines, Spheroids, Cellular, Cell Culture Techniques, Drug Resistance, Neoplasm, Cell Line, Tumor, Microfluidic Analytical Techniques, Mice, Time-Lapse Imaging, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.